Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Chemotherapy Induced Thrombocytopenia is a common side-effect of bone marrow suppression as a
result of a chemotherapy treatment. AS101 is a tellurium based small compound with
immunomodulating characteristics which attributed to the direct inhibition of the
anti-inflammatory cytokine IL-10. AS101 was previously shown to induce a significant
reduction in thrombocytopenia that accompany cancer therapy with no major toxicity . This
phase II randomized open study will evaluate the efficacy of AS101 for the treatment of
chemotherapy induced thrombocytopenia in patients with various solid tumors.